Litigation Details for BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)
✉ Email this page to a colleague
BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-06-13 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-03-19 |
| Cause | 35:271 Patent Infringement | Assigned To | Stanley R. Chesler |
| Jury Demand | None | Referred To | Cathy L. Waldor |
| Patents | 10,307,417; 8,420,663; 8,524,276; 8,956,651; 9,180,125; 9,314,461; 9,492,445; 9,724,343 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-06-13 | 1 | Complaint | United States Patent No. 10,307,417 (“the ’417 patent”) arising under the United States patent laws, Title… THE PATENT IN SUIT 26. The U.S. Patent and Trademark Office (“PTO”…PTO”) issued the ’417 patent on June 4, 2019. The ’417 patent claims, inter alia, compositions of methylnaltrexone…the ’417 patent and have the right to sue for infringement thereof. A copy of the ’417 patent is attached…Defendants. COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs Bausch Health Companies | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
